Clinical Trial Goal
To find out:
- The highest dose of abemaciclib that's safe to give with ruxolitinib
- If the combination of abemaciclib and ruxolitinib is safe and works well to treat myelofibrosis
You may be able to join this trial if you:
- Are 18 years or older
- Have myelofibrosis. Some examples include:
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
- Primary myelofibrosis
- Have not been treated with a drug that targets CDK4 or CDK6. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Abemaciclib is a small molecule inhibitor that blocks CDK4 and CDK6 in certain cells.
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Abemaciclib – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Ruxolitinib – A pill that you take by mouth 2 times each day
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved abemaciclib.
Locations
Sponsors
collaborator: Eli Lilly and Company, collaborator: Incyte Corporation, lead: Memorial Sloan Kettering Cancer Center
